MarketCap
Facebook
X
TelegramPRA Health Sciences, Inc. Revenue 2011-2026 | PRAH
Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.
Traditionally defined as follows:Revenue = Price * Quantity of productsRevenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.[1]
This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.
Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.
Annual Revenue PRA Health Sciences, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 3.18 B | 3.07 B | 2.87 B | 2.26 B | 1.81 B | 1.61 B | 1.46 B | - | 700 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 3.18 B | 700 M | 2.12 B |
References
- Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).
Revenue of other stocks in the Diagnostics research industry
| Issuer | Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
128 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Heska Corporation
HSKA
|
257 M | - | - | $ 1.31 B |  USA |
 |
Fulgent Genetics
FLGT
|
323 M | $ 17.11 | -1.55 % | $ 527 M | USA |
 |
ICON Public Limited Company
ICLR
|
5.48 B | $ 116.78 | 0.18 % | $ 9.63 B |  Irlanda |
 |
Agilent Technologies
A
|
6.32 B | $ 114.96 | 0.15 % | $ 34.9 B | USA |
|
Akumin
AKU
|
750 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Illumina
ILMN
|
4.37 B | $ 144.41 | -0.29 % | $ 23 B | USA |
 |
Co-Diagnostics
CODX
|
622 K | $ 5.07 | 36.66 % | $ 6.74 M | USA |
 |
Castle Biosciences
CSTL
|
344 M | $ 20.15 | -1.9 % | $ 584 M | USA |
 |
Aspira Women's Health
AWH
|
343 K | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
11.7 M | - | -61.36 % | $ 2.46 M | USA |
 |
Biocept
BIOC
|
25.9 M | - | -13.05 % | $ 7.29 M | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
73.7 M | - | - | $ 562 M |  Britain |
 |
Guardant Health
GH
|
982 M | $ 118.95 | 0.8 % | $ 14.9 B | USA |
 |
CareDx, Inc
CDNA
|
380 M | $ 21.63 | 0.28 % | $ 1.15 B | USA |
 |
Chembio Diagnostics
CEMI
|
49.5 M | - | 0.22 % | $ 16.8 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
6.37 M | - | -20.0 % | $ 1.06 M | USA |
 |
Interpace Biosciences
IDXG
|
38.7 M | $ 1.82 | 1.11 % | $ 8.05 M | USA |
 |
Lantheus Holdings
LNTH
|
1.54 B | $ 103.0 | 9.03 % | $ 6.95 B | USA |
 |
Global Cord Blood Corporation
CO
|
1.24 B | - | - | $ 399 M |  China |
 |
Mettler-Toledo International
MTD
|
4.03 B | $ 1 103.09 | 1.16 % | $ 22.7 B |  Schweiz |
 |
Fluidigm Corporation
FLDM
|
138 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
7.66 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
651 M | - | 0.12 % | $ 80.1 M | China |
 |
NeoGenomics
NEO
|
727 M | $ 9.23 | 1.32 % | $ 1.18 B | USA |
 |
National Research Corporation
NRC
|
137 M | $ 19.08 | 0.21 % | $ 427 M | USA |
 |
DermTech
DMTK
|
15.3 M | - | -11.32 % | $ 2.94 M | USA |
 |
Natera
NTRA
|
820 M | $ 203.19 | -0.25 % | $ 20 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 160.3 | 0.91 % | $ 7.95 B | USA |
 |
Enzo Biochem
ENZ
|
31.9 M | - | -8.98 % | $ 14.8 K | USA |
 |
Medpace Holdings
MEDP
|
2.53 B | $ 432.8 | 0.63 % | $ 12.5 B | USA |
 |
Exact Sciences Corporation
EXAS
|
3.25 B | - | - | $ 19.8 B | USA |
 |
Myriad Genetics
MYGN
|
824 M | $ 3.82 | -2.3 % | $ 354 M | USA |
 |
Personalis
PSNL
|
69.6 M | $ 8.47 | 2.67 % | $ 756 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
17.8 B | $ 26.95 | -0.74 % | $ 25.6 B |  Niderland |
 |
Senseonics Holdings
SENS
|
35.3 M | $ 6.34 | 2.92 % | $ 265 M | USA |
 |
QIAGEN N.V.
QGEN
|
2.25 B | - | - | $ 10.6 B | Niderland |
 |
Soleno Therapeutics
SLNO
|
190 M | - | - | $ 2.69 B | USA |
 |
Biomerica
BMRA
|
5.31 M | $ 2.49 | 2.05 % | $ 5.72 M | USA |
 |
Twist Bioscience Corporation
TWST
|
377 M | $ 60.57 | 2.95 % | $ 3.62 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
14 B | $ 259.93 | 1.63 % | $ 21.6 B | USA |
 |
Thermo Fisher Scientific
TMO
|
44.6 B | $ 448.28 | -0.24 % | $ 169 B | USA |
 |
Trinity Biotech plc
TRIB
|
61.6 M | $ 0.6 | -3.7 % | $ 216 M | Irlanda |
 |
Motus GI Holdings
MOTS
|
319 K | - | -34.28 % | $ 263 K |  Israel |
 |
Neogen Corporation
NEOG
|
895 M | $ 8.9 | 0.45 % | $ 1.93 B | USA |
 |
Waters Corporation
WAT
|
932 M | $ 342.37 | 0.4 % | $ 20.4 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
11 B | $ 195.21 | 0.72 % | $ 21.7 B | USA |